Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; magnesium stearate; maize starch; purified water; povidone; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - bosentan astron is indicated for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bosentan monohydrate, quantity: 64.54 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; purified water; povidone; magnesium stearate; pregelatinised maize starch; sodium starch glycollate type a; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - bosentan intas is indicated for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; sodium starch glycollate type a; maize starch; povidone; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - bosentan intas is indicated for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; maize starch; povidone; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - bosentan astron is indicated for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; glycerol dibehenate; povidone; maize starch; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bosentan monohydrate, quantity: 129.083 mg - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; sodium starch glycollate type a; pregelatinised maize starch; povidone; glycerol dibehenate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

European Union - English - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with world health organization (who) functional class iii. efficacy has been shown in:primary (idiopathic and familial) pah;pah secondary to scleroderma without significant interstitial pulmonary disease;pah associated with congenital systemic-to-pulmonary shunts and eisenmenger’s physiology.some improvements have also been shown in patients with pah who functional class ii.stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease.

European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v.   - bosentan (as monohydrate) - scleroderma, systemic; hypertension, pulmonary - antihypertensives, - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii.efficacy has been shown in: , primary (idiopathic and familial) pah;, pah secondary to scleroderma without significant interstitial pulmonary disease;, pah associated with congenital systemic-to-pulmonary shunts and eisenmenger's physiology. , some improvements have also been shown in patients with pah who functional class ii. tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; glyceryl behenate; povidone; maize starch; pregelatinised maize starch; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; purified talc; triacetin; purified water; strong ammonia solution; ethylcellulose; oleic acid; medium chain triglycerides - bosentan viatris is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology ,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bosentan monohydrate, quantity: 129.082 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; maize starch; pregelatinised maize starch; sodium starch glycollate type a; sodium lauryl sulfate; glyceryl behenate; titanium dioxide; hypromellose; purified talc; triacetin; purified water; strong ammonia solution; ethylcellulose; oleic acid; medium chain triglycerides - bosentan viatris is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology ,in patients with who functional class ii, iii or iv symptoms